Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes to worsening metabolic health and an increased risk of type 2 diabetes.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Tirzepatide may confer larger increases in testosterone levels among men with metabolic hypogonadism than testosterone ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

The team found that the tirzepatide-treated mice lost about 20 percent of their body weight, mostly from reduced fat mass. In ...

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...